| Literature DB >> 29636625 |
Yanpeng Zhang1,2, Zhuocheng Li2, Xiaolong He1, Fanglin Ding2, Weiqing Wu2, Yong Luo2, Bing Fan2, Hong Cao1.
Abstract
PURPOSE: Acinetobacter baumannii is an important pathogen in the nosocomial infections worldwide. Combining with carbapenemases, efflux pumps and outer membrane proteins (OMPs) have been thought to affect the development of carbapenem resistance in A. baumannii. This study aimed to investigate the contributions of different efflux pumps and OMPs in developing carbapenem resistance in a clinical isolate of A. baumannii and reveal the possible mechanism of overproduction of main efflux pumps. PATIENTS AND METHODS: In this study, an imipenem-susceptible clinical isolate was identified as A. baumannii and named SZE. Several common carbapenemases were detected by polymerase chain reaction (PCR). Imipenem-selected mutants were selected from SZE by serial subcultivations on Mueller-Hinton agar, and the minimum inhibitory concentration (MIC) was detected. Gene expressions of four families of efflux pumps, five OMPs, and blaOXA-51 were determined by reverse transcription quantitative PCR, and comparisons were made between SZE strain and the imipenem-selected mutants. The adeRS system in SZE and its mutant was sequenced and aligned.Entities:
Keywords: Acinetobacter baumannii; efflux pump; imipenem; multidrug resistance; outer membrane protein
Year: 2018 PMID: 29636625 PMCID: PMC5880185 DOI: 10.2147/IDR.S151423
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
DNA sequence of primers and amplicon size
| Target genes | Sequence of primers | Amplicon (bps) |
|---|---|---|
| GAGTCTAATGGCGGTGGTTC | 110 | |
| ATTGCTTCATCTGCTGGTTG | ||
| GAGGGAGTGCTCGAATTTGT | 2293 | |
| GCTCAGCTTGAGCGACTTCT | ||
| AGCTAACGCGATAAGTAGACCG | 137 | |
| TGTCAAGGCCAGGTAAGGTTC | ||
| GCAGAGCGTACTCGGAATGT | 101 | |
| CCACTGAAACCCCATCCCAA | ||
| TTCGGTGGCTCATACGCAAT | 137 | |
| GGAGCACCACCTAACTGACC | ||
| ACAGGGTAGTCGTTTTGGGC | 107 | |
| TCCACCTAGAAACCGTTGCC | ||
| TGTGCAACTCTTTCCTGCATT | 140 | |
| GCAATGATTGAGCTTGTACGCTAT | ||
| ACGATTGATGCAACGGTAATGC | 82 | |
| TCCATAAAAGCTGATTGGCAGT | ||
| CGTTGAGAAGCTGAGGTGGT | 111 | |
| TTCAAGTGCGCTTTGGATGC | ||
| CGCAGCTCTTGGTATCGAGT | 235 | |
| ACCACGGTTTACGCCATCAA | ||
| CCAAGGTGAAATCTTGGCAC | 166 | |
| TTCAATTGCAGGGGTCCAGG | ||
| ACCTTTGATGTCAGCTTCGC | 226 | |
| TGCTGTTAACCAAACTGCTGC | ||
| GGCGGATGAAGCTGTTGTTC | 102 | |
| GCACCACCGTAACCTGTAGT | ||
| AACTATGCGGTGCTCAAC | 218 | |
| GGTGAATTACTTGGTGATGC | ||
| TTTGGTCAGGCGCAGGTATT | 86 | |
| ACCAATGCAGGCAGCTAAGT | ||
| ATTCTGCATTCACTCGCCCA | 232 | |
| CCTGACGTTCCTCATCCACC | ||
| TGCTGCGGATGGTATAGCTG | 84 | |
| ACACTATGTGGACCAGTCGC | ||
| GAATATGTGCCAGCCTCTAC | 245 | |
| GCATTACCGAAACCAATACG | ||
| TGGGTGGAGCAAGCTAATGG | 81 | |
| ACGAATAGAACCAGACATTCCTTCT | ||
| TAATGCTTTGATCGGCCTTG | 353 | |
| TGGATTGCACTTCATCTTGG | ||
| GACAATTACACCTATACAAGAAG | 599 | |
| AAACCCACATACCAACCC | ||
| ATGGAATTGCCCAATATTATGCACCCGG | 813 | |
| TCAGCGCAGCTTGTCGGCCATG | ||
| CAAGGCCGATCA AAGCATTA | 1208 | |
| GTGTCATAGTATTCGTCG | ||
| ATGAGAGTATTCAACAAAGTTGTTGA | 1014 | |
| CTTATACGCTCAAAACTTAA | ||
| GTGTACAGAGATTTAATCCAAACT | 366 | |
| TAAAGGGCCATCATAAAGTCTAA |
Abbreviations: F, forward; R, reverse.
MICs of Acinetobacter baumannii SZE strain (G1) and its imipenem-selected derivatives
| Antimicrobial agents | MIC (μg/mL)
| |||||
|---|---|---|---|---|---|---|
| G1 | G10 (+EI) | G20 (+EI) | G30 (+EI) | G45 (+EI) | G50 (+EI) | |
| Ampicillin | 128 (4) | 128 (4) | 256 (4) | 512 (8) | 512 (8) | 512 (8) |
| Ceftazidime | 64 (32) | 64 (32) | 128 (32) | 256 (32) | 256 (32) | 256 (32) |
| Imipenem | 0.125 (≤0.125) | 0.5 (≤0.125) | 4 (≤0.125) | 8 (≤0.125) | 8 (≤0.125) | 8 (≤0.125) |
| Meropenem | 0.125 (≤0.125) | 1 (≤0.125) | 4 (≤0.125) | 8 (≤0.125) | 8 (≤0.125) | 8 (≤0.125) |
| Ampicillin/sulbactam | 64 (4) | 64 (4) | 128 (4) | 128 (4) | 128 (4) | 128 (4) |
| Amikacin | 32 (2) | 32 (2) | 64 (2) | 64 (2) | 64 (2) | 64 (2) |
| Gentamicin | 32 (≤4) | 32 (≤4) | 32 (≤4) | 64 (≤4) | 64 (≤8) | 64 (≤8) |
| Kanamycin | 64 (4) | 64 (4) | 128 (4) | 256 (4) | 256 (4) | 256 (4) |
| Tobramycin | 64 (8) | 128 (8) | 128 (8) | 256 (8) | 256 (8) | 256 (8) |
| Ciprofloxacin | 16 (8) | 32 (8) | 128 (8) | 128 (8) | 128 (8) | 128 (8) |
| Levofloxacin | 32 (4) | 32 (4) | 64 (4) | 128 (4) | 128 (4) | 128 (4) |
| Tetracycline | 32 (4) | 32 (4) | 64 (4) | 64 (4) | 64 (4) | 64 (4) |
Notes:
Breakpoint of imipenem and meropenem: sensitive, MIC ≤4 μg/mL; intermediate, MIC =8 μg/mL; resistant, MIC ≥16 μg/mL (CLSI, 2015);
“G” indicates subculturings under the imipenem-selected stress;
(+EI) indicates MICs in the presence of efflux pump inhibitor CCCP.
Abbreviations: CCCP, carbonyl cyanide 3-chlorophenylhydrazone; CLSI, Clinical Laboratory Standards Institute; MIC, minimum inhibitory concentrations.
Figure 1Constant monitoring of imipenem susceptibility pattern of SZE strain using Kirby–Bauer agar diffusion method in 58 subcultivations. The white triangle dotted line shows diameter with an efflux pump inhibitor, and the black triangle dotted line indicates diameter without an efflux pump inhibitor. The smooth line indicates diameter of the zone of 13 mm, which is the breakpoint of imipenem resistance according to the guidelines of the CLSI.
Abbreviations: EI, efflux pump inhibitor; AST, antimicrobial susceptibility testing; CLSI, Clinical Laboratory Standards Institute.
Figure 2Changes in the relative expression of genes of efflux pump families, outer membrane proteins, and bla under the stress of imipenem resistance between G1, G10, G20, and G45 strains. (A) Genes of the RND family of efflux pumps (adeB, adeG, and adeJ) in G1, G10, G20, and G45; (B) genes of the MATE family of efflux pumps (abeM), SMR family of efflux pumps (abeS), genes of the MFS family of efflux pumps (craA, amvA, and tetB); and (C) outer membrane protein genes (ompA, ompW, omp33, oprD, and carO) and blaOXA-51. *p<0.01, **p<0.001; the change of expression between G1 and G45 was not significant.
Abbreviation: NS, not significant.